General Instructions
Download the Week 8 Medication TableLinks to an external site. and complete the required information using the template.
Include the following sections (detailed criteria listed below and in the grading rubric)
- For each medication listed, complete the following:
- Provide FDA Indication (include stages), neurotransmitters Affected/Mechanism of Action, and Target Symptoms.
- Include formulation (Short-acting, intermediate-acting, or long-acting), duration of action, half-life, and CYP 450 enzyme information.
- List notable side effects and precautions.
- Include Patient Education Instructions.
Solution
| Drug Name and Class
|
FDA Indication (include stages )
Neurotransmitters Affected/Mechanism of Action Target Symptoms |
Short-acting, intermediate-acting, or long-acting.
Duration of Action and Half-life (T1/2), CYP 450 enzyme |
Notable Side Effects/Precautions /Patient Education Instructions |
| Donepezil (Aricept) | Alzheimer’s disease – mild, moderate, and severe
Acetylcholine enzyme inhibitor
Reversibly but noncompetitively inhibits centrally acting acetylcholinesterase to make more Ach available.
Increase Ach compensates in part for degenerating cholinergic neurons in neocortex that regulate memory
Does not inhibit butyrylcholinesterase
May release growth factors or interfere with amyloid deposition
Targets memory loss in Alzheimers, behavioral symptoms in Alzheimers, memory loss in other dementias
|
Metabolized by CYP450 2D6 and CYP450 3A4
Elimination half-life approximately 70 hours |
Nausea, diarrhea, vomiting, appetite loss, increased gastric acid secretion, weight loss, insomnia, dizziness
May exacerbate asthma or pulmonary disease. Increased gastric secretion may increase the risk of ulcers, bradycardia or heartblock may occur in patients with or without cardiac impairment.
Dramatic reversal of symptoms not generally seen with cholinesterase inhibitors. Treats behavioral and psychological symptoms of Alzheimers dementia as well as cognitive symptoms. Taper to avoid withdrawal. Discontinuation of medication may lead to notable deterioration in memory and behavior which may not be restored when drug is restarted or another cholinesterase inhibitor is initiated. |